University College London | Centre for Clinical Microbiology
Status and phase
Conditions
Treatments
About
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, and Pharmacokinetics of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Full description
This study will continue to evaluate the safety, tolerability, PK, and efficacy of AOC 1020 in participants who were treated in the randomized, placebo-controlled, Phase 1/2 AOC 1020-CS1 clinical study.
Participants from AOC 1020-CS1 are eligible to enroll in AOC 1020-CS2 if they have satisfactorily completed AOC 1020-CS1. All participants who enroll in AOC 1020-CS2 will receive AOC 1020 regardless of whether they received AOC 1020 or placebo in AOC 1020-CS1. Dosing will occur quarterly (i.e., every 13 weeks).
The total duration of active treatment in AOC 1020-CS2 is approximately 24 months. Once participants have completed active treatment, they will be followed through a 9-month safety follow-up period, which consists of a minimum of quarterly visits (which may be telehealth visits) to monitor for adverse events (AEs), concomitant medications, and pregnancy status (as applicable). Total duration on study is up to approximately 33 months (2 years 9 months), excluding the potential 3-month screening period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Ability to provide written informed consent (signed and dated) and any authorizations required by local law and be willing and able to comply with all study requirements.
Completion of AOC 1020-CS1 with the following as judged by the Investigator and Sponsor:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
72 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal